Lista de obras - Hans Hagberg - Dominio Público Uruguay

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

artículo científico publicado en 2016

A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia

artículo científico publicado en 2018

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

artículo científico publicado en 2003

A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma

artículo científico publicado en 2013

CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial

artículo científico publicado en 2003

Change of initial staging at early remission evaluation with FDG-PET/CT in Hodgkin lymphoma: a report of two cases

artículo científico publicado en 2010

Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up

article

Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden

artículo científico publicado en 2008

Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis

artículo científico publicado en 2005

First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

artículo científico publicado en 2015

Heterogeneous somatic hypermutation status confounds the cell of origin in hairy cell leukemia

artículo científico publicado en 2005

High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results.

artículo científico publicado en 2008

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

artículo científico publicado en 2003

Higher concentrations of specific polychlorinated biphenyl congeners in adipose tissue from non-Hodgkin's lymphoma patients compared with controls without a malignant disease ⬇️

artículo científico publicado el 1 de octubre de 1996

Long term risk of infections in Hodgkin lymphoma long‐term survivors ⬇️

artículo científico publicado el 7 de abril de 2011

Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation.

artículo científico publicado en 2003

Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group

artículo científico publicado en 2008

Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation - experiences from a prospective, clinical, observational study

artículo científico publicado en 2016

Occupation and occupational exposure to UV light as risk factors for hairy cell leukaemia evaluated in a case-control study ⬇️

artículo científico publicado el 1 de octubre de 1997

Occupational exposures, animal exposure and smoking as risk factors for hairy cell leukaemia evaluated in a case-control study

artículo científico publicado en 1998

Outcome for young high-risk aggressive B-cell lymphoma patients treated with CHOEP-14 and rituximab (R-CHOEP-14)

artículo científico publicado en 2006

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

artículo científico publicado en 2003

Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma

artículo científico publicado en 2010

Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study.

artículo científico publicado en 2011

Population-based experience on primary central nervous system lymphoma 2000-2012: the incidence is increasing

artículo científico publicado en 2017

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma

artículo científico publicado en 2016

Reply to M. Sorigue et al

artículo científico publicado en 2019

Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma

artículo científico publicado en 2012

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

artículo científico publicado en 2010

Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs: results of a clinical trial

artículo científico publicado en 2002

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

artículo científico publicado en 2019

Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group

artículo científico publicado en 2014

T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab.

artículo científico publicado en 2011

The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy

artículo científico publicado en 2020

Treatment outcome in T-cell lymphoblastic lymphoma in adults - a population-based study from the Swedish Lymphoma Registry

artículo científico publicado en 2014

Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas

artículo científico

Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01

Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)

scientific article published on 01 June 2018

Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients

artículo científico publicado en 2011

[Limit investigation in cancer of unknown primary site]

artículo científico publicado en 2005

Lista de obras de Hans Hagberg

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma

CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial

Change of initial staging at early remission evaluation with FDG-PET/CT in Hodgkin lymphoma: a report of two cases

Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up

Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden

Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis

First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

Heterogeneous somatic hypermutation status confounds the cell of origin in hairy cell leukemia

High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results.

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

Higher concentrations of specific polychlorinated biphenyl congeners in adipose tissue from non-Hodgkin's lymphoma patients compared with controls without a malignant disease ⬇️

Long term risk of infections in Hodgkin lymphoma long‐term survivors ⬇️

Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation.

Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group

Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation - experiences from a prospective, clinical, observational study

Occupation and occupational exposure to UV light as risk factors for hairy cell leukaemia evaluated in a case-control study ⬇️

Occupational exposures, animal exposure and smoking as risk factors for hairy cell leukaemia evaluated in a case-control study

Outcome for young high-risk aggressive B-cell lymphoma patients treated with CHOEP-14 and rituximab (R-CHOEP-14)

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma

Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study.

Population-based experience on primary central nervous system lymphoma 2000-2012: the incidence is increasing

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma

Reply to M. Sorigue et al

Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs: results of a clinical trial

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group

T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab.

The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy

Treatment outcome in T-cell lymphoblastic lymphoma in adults - a population-based study from the Swedish Lymphoma Registry

Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas

Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01

Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)

Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients

[Limit investigation in cancer of unknown primary site]